<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Nelson Pediatrics ‚Äî Part XIII: Allergic Disorders</title>
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@400;700;900&family=DM+Sans:wght@300;400;500;600&family=DM+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
  :root {
    --bg: #0d1117; --surface: #161b22; --surface2: #1c2333; --border: #30363d;
    --accent: #e8a44a; --accent2: #5caaee; --accent3: #63d98a; --danger: #f07a7a;
    --text: #e6edf3; --text-muted: #8b949e; --text-dim: #484f58;
  }
  * { margin: 0; padding: 0; box-sizing: border-box; }
  body { background: var(--bg); color: var(--text); font-family: 'DM Sans', sans-serif; font-weight: 300; line-height: 1.75; min-height: 100vh; }
  body::before { content: ''; position: fixed; inset: 0; background-image: url("data:image/svg+xml,%3Csvg viewBox='0 0 256 256' xmlns='http://www.w3.org/2000/svg'%3E%3Cfilter id='noise'%3E%3CfeTurbulence type='fractalNoise' baseFrequency='0.9' numOctaves='4' stitchTiles='stitch'/%3E%3C/filter%3E%3Crect width='100%25' height='100%25' filter='url(%23noise)' opacity='0.04'/%3E%3C/svg%3E"); pointer-events: none; z-index: 0; opacity: 0.4; }
  .page-wrap { position: relative; z-index: 1; max-width: 920px; margin: 0 auto; padding: 0 24px 80px; }
  .hero { padding: 72px 0 48px; border-bottom: 1px solid var(--border); margin-bottom: 48px; position: relative; overflow: hidden; }
  .hero::after { content: 'XIII'; position: absolute; right: -10px; top: 10px; font-family: 'Playfair Display', serif; font-size: 140px; font-weight: 900; color: var(--border); line-height: 1; pointer-events: none; user-select: none; }
  .hero-tag { display: inline-flex; align-items: center; gap: 8px; background: rgba(232,164,74,0.1); border: 1px solid rgba(232,164,74,0.3); color: var(--accent); font-family: 'DM Mono', monospace; font-size: 11px; letter-spacing: 0.12em; text-transform: uppercase; padding: 5px 12px; border-radius: 4px; margin-bottom: 20px; }
  .hero-tag::before { content: ''; width: 6px; height: 6px; border-radius: 50%; background: var(--accent); animation: pulse 2s ease-in-out infinite; }
  @keyframes pulse { 0%,100%{opacity:1;transform:scale(1)}50%{opacity:.4;transform:scale(.8)} }
  .hero h1 { font-family: 'Playfair Display', serif; font-size: clamp(28px,4.5vw,48px); font-weight: 900; line-height: 1.1; margin-bottom: 12px; color: var(--text); }
  .hero h1 span { color: var(--accent); }
  .hero-sub { font-size: 15px; color: var(--text-muted); max-width: 560px; margin-bottom: 28px; }
  .hero-meta { display: flex; gap: 24px; flex-wrap: wrap; }
  .meta-pill { display: flex; align-items: center; gap: 6px; font-size: 12px; color: var(--text-muted); font-family: 'DM Mono', monospace; }
  .meta-pill .dot { width: 8px; height: 8px; border-radius: 50%; }
  .search-bar { position: sticky; top: 0; z-index: 100; background: rgba(13,17,23,0.92); backdrop-filter: blur(12px); border-bottom: 1px solid var(--border); padding: 12px 0; margin-bottom: 36px; }
  .search-inner { max-width: 920px; margin: 0 auto; padding: 0 24px; display: flex; align-items: center; gap: 12px; }
  .search-input { flex: 1; background: var(--surface); border: 1px solid var(--border); border-radius: 8px; padding: 8px 14px 8px 36px; color: var(--text); font-family: 'DM Sans', sans-serif; font-size: 14px; outline: none; transition: border-color 0.2s; background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='16' height='16' viewBox='0 0 24 24' fill='none' stroke='%238b949e' stroke-width='2'%3E%3Ccircle cx='11' cy='11' r='8'/%3E%3Cpath d='m21 21-4.35-4.35'/%3E%3C/svg%3E"); background-repeat: no-repeat; background-position: 10px center; }
  .search-input:focus { border-color: var(--accent); }
  .search-input::placeholder { color: var(--text-dim); }
  .chapter-count { font-family: 'DM Mono', monospace; font-size: 11px; color: var(--text-muted); white-space: nowrap; }
  .stats-strip { display: grid; grid-template-columns: repeat(auto-fit,minmax(180px,1fr)); gap: 12px; margin-bottom: 48px; }
  .stat-card { background: var(--surface); border: 1px solid var(--border); border-radius: 10px; padding: 16px 18px; transition: border-color 0.2s,transform 0.2s; }
  .stat-card:hover { border-color: var(--accent); transform: translateY(-2px); }
  .stat-label { font-family: 'DM Mono', monospace; font-size: 10px; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 6px; }
  .stat-value { font-family: 'Playfair Display', serif; font-size: 22px; font-weight: 700; color: var(--accent); }
  .stat-desc { font-size: 12px; color: var(--text-muted); margin-top: 2px; }
  .hiyield { background: linear-gradient(135deg,rgba(232,164,74,0.08),rgba(232,164,74,0.03)); border: 1px solid rgba(232,164,74,0.25); border-left: 3px solid var(--accent); border-radius: 10px; padding: 20px 24px; margin-bottom: 48px; }
  .hiyield-header { display: flex; align-items: center; gap: 8px; font-family: 'DM Mono', monospace; font-size: 11px; text-transform: uppercase; letter-spacing: 0.12em; color: var(--accent); margin-bottom: 14px; }
  .hiyield ul { list-style: none; display: grid; grid-template-columns: repeat(auto-fill,minmax(300px,1fr)); gap: 8px; }
  .hiyield ul li { font-size: 13px; color: var(--text); padding-left: 16px; position: relative; line-height: 1.5; }
  .hiyield ul li::before { content: '‚ñ∏'; position: absolute; left: 0; color: var(--accent); font-size: 11px; }
  strong.hl  { color: var(--accent);  font-weight: 600; }
  strong.hl2 { color: var(--accent2); font-weight: 600; }
  strong.hl3 { color: var(--accent3); font-weight: 600; }
  strong.hld { color: var(--danger);  font-weight: 600; }
  .section-label { font-family: 'DM Mono', monospace; font-size: 11px; text-transform: uppercase; letter-spacing: 0.14em; color: var(--text-muted); margin-bottom: 16px; display: flex; align-items: center; gap: 10px; }
  .section-label::after { content: ''; flex: 1; height: 1px; background: var(--border); }
  .chapters-grid { display: flex; flex-direction: column; gap: 12px; margin-bottom: 48px; }
  .chapter-card { background: var(--surface); border: 1px solid var(--border); border-radius: 12px; overflow: hidden; transition: border-color 0.2s,box-shadow 0.2s; }
  .chapter-card:hover { border-color: rgba(92,170,238,0.4); box-shadow: 0 4px 20px rgba(0,0,0,0.3); }
  .chapter-header { display: flex; align-items: center; gap: 14px; padding: 16px 20px; cursor: pointer; user-select: none; }
  .ch-num { font-family: 'DM Mono', monospace; font-size: 11px; font-weight: 500; color: var(--text-muted); background: var(--surface2); border: 1px solid var(--border); border-radius: 6px; padding: 3px 8px; white-space: nowrap; min-width: 52px; text-align: center; }
  .ch-title { flex: 1; font-size: 15px; font-weight: 500; color: var(--text); }
  .ch-tags { display: flex; gap: 6px; flex-wrap: wrap; }
  .tag { font-family: 'DM Mono', monospace; font-size: 9px; text-transform: uppercase; letter-spacing: 0.08em; padding: 2px 7px; border-radius: 4px; border: 1px solid; }
  .tag-hiy  { color: var(--accent);  border-color: rgba(232,164,74,0.3);  background: rgba(232,164,74,0.08); }
  .tag-eth  { color: var(--accent2); border-color: rgba(92,170,238,0.3);  background: rgba(92,170,238,0.08); }
  .tag-soc  { color: var(--accent3); border-color: rgba(99,217,138,0.3);  background: rgba(99,217,138,0.08); }
  .tag-crit { color: var(--danger);  border-color: rgba(240,122,122,0.3); background: rgba(240,122,122,0.08); }
  .ch-toggle { color: var(--text-muted); font-size: 18px; transition: transform 0.3s; line-height: 1; }
  .chapter-card.open .ch-toggle { transform: rotate(180deg); }
  .chapter-body { display: none; padding: 0 20px 20px; border-top: 1px solid var(--border); animation: slideIn 0.2s ease; }
  @keyframes slideIn { from{opacity:0;transform:translateY(-6px)} to{opacity:1;transform:translateY(0)} }
  .chapter-card.open .chapter-body { display: block; }
  .key-points { list-style: none; display: flex; flex-direction: column; gap: 6px; margin-top: 10px; }
  .key-points li { font-size: 13.5px; color: var(--text); padding: 8px 12px; background: var(--surface2); border-radius: 6px; border-left: 2px solid var(--border); line-height: 1.6; }
  .key-points li.imp  { border-left-color: var(--accent); }
  .key-points li.crit { border-left-color: var(--danger); }
  .key-points li.note { border-left-color: var(--accent2); }
  .mnemonic { margin-top: 12px; background: rgba(99,217,138,0.07); border: 1px dashed rgba(99,217,138,0.25); border-radius: 8px; padding: 10px 14px; font-size: 13px; color: var(--accent3); }
  .mnemonic::before { content: 'üí° '; }
  .progress-wrap { margin-bottom: 32px; }
  .progress-label { font-family: 'DM Mono', monospace; font-size: 11px; color: var(--text-muted); margin-bottom: 6px; display: flex; justify-content: space-between; }
  .progress-bar { height: 4px; background: var(--border); border-radius: 2px; overflow: hidden; }
  .progress-fill { height: 100%; background: linear-gradient(90deg,var(--accent),var(--accent2)); border-radius: 2px; width: 0%; transition: width 0.4s ease; }
  .footer { margin-top: 60px; padding-top: 24px; border-top: 1px solid var(--border); display: flex; justify-content: space-between; align-items: center; font-family: 'DM Mono', monospace; font-size: 11px; color: var(--text-dim); }
  .chapter-card.hidden { display: none; }
  @media(max-width:600px){ .hero::after{font-size:80px} .stats-strip{grid-template-columns:repeat(2,1fr)} .hiyield ul{grid-template-columns:1fr} .ch-tags{display:none} }
</style>
</head>
<body>

<div class="search-bar">
  <div class="search-inner">
    <input class="search-input" type="text" id="searchInput" placeholder="Search chapters, topics, keywords‚Ä¶" oninput="filterChapters()">
    <span class="chapter-count" id="chapterCount">12 chapters</span>
  </div>
</div>

<div class="page-wrap">

  <div class="hero">
    <div class="hero-tag">Nelson Textbook of Pediatrics ¬∑ 22nd Edition ¬∑ 2024</div>
    <h1>Part <span>XIII</span><br>Allergic Disorders</h1>
    <p class="hero-sub">Mechanisms and clinical management of IgE-mediated and non-IgE-mediated allergic diseases ‚Äî asthma, rhinitis, food allergy, anaphylaxis, urticaria, angioedema, and drug/insect sting reactions in children.</p>
    <div class="hero-meta">
      <span class="meta-pill"><span class="dot" style="background:var(--accent)"></span>Chapters 182‚Äì193</span>
      <span class="meta-pill"><span class="dot" style="background:var(--accent2)"></span>12 Chapters</span>
      <span class="meta-pill"><span class="dot" style="background:var(--accent3)"></span>Heavily Tested on Boards</span>
    </div>
  </div>

  <div class="stats-strip">
    <div class="stat-card"><div class="stat-label">Chapters</div><div class="stat-value">12</div><div class="stat-desc">Ch. 182‚Äì193</div></div>
    <div class="stat-card"><div class="stat-label">Core Diseases</div><div class="stat-value">6</div><div class="stat-desc">Asthma ¬∑ Rhinitis ¬∑ Eczema ¬∑ Food ¬∑ Anaphylaxis ¬∑ Drug</div></div>
    <div class="stat-card"><div class="stat-label">Key Biologics</div><div class="stat-value">5+</div><div class="stat-desc">Dupilumab ¬∑ Omalizumab ¬∑ Mepolizumab ¬∑ Benralizumab‚Ä¶</div></div>
    <div class="stat-card"><div class="stat-label">Board Relevance</div><div class="stat-value">‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ</div><div class="stat-desc">Asthma & anaphylaxis = highest-yield allergic topics</div></div>
  </div>

  <div class="hiyield">
    <div class="hiyield-header">‚ö° High-Yield Quick Reference ‚Äî Part XIII</div>
    <ul>
      <li>Asthma: reversible airway obstruction + hyperresponsiveness + inflammation; FEV‚ÇÅ/FVC &lt;0.8 + &gt;12% bronchodilator response confirms</li>
      <li>Asthma step therapy: SABA PRN ‚Üí low-dose ICS ‚Üí ICS + LABA ‚Üí high-dose ICS + LABA ‚Üí biologics/oral steroids</li>
      <li>Anaphylaxis: <strong class="hld">IM epinephrine 0.01 mg/kg (max 0.5 mg) anterolateral thigh ‚Äî ALWAYS first-line</strong></li>
      <li>Biphasic anaphylaxis: recurrence 4‚Äì12h later ‚Üí observe ‚â•4‚Äì6h after reaction resolves</li>
      <li>Allergic rhinitis: intranasal corticosteroids = most effective single agent (not antihistamines)</li>
      <li>Top 9 food allergens: milk, egg, peanut, tree nuts, fish, shellfish, wheat, soy, sesame</li>
      <li>LEAP trial: early peanut introduction (4‚Äì11 mo) ‚Üí ‚Üìpeanut allergy 80% in high-risk infants</li>
      <li>FPIES: non-IgE; profuse vomiting 1‚Äì4h after trigger; milk/soy most common; ondansetron + IV fluids</li>
      <li>Atopic dermatitis: moisturizers + topical steroids first-line; dupilumab for moderate-severe</li>
      <li>Urticaria &lt;6 wks = acute (usually viral/IgE); &gt;6 wks = chronic (idiopathic 80‚Äì90%); treat with non-sedating antihistamines</li>
      <li>Penicillin allergy: true IgE-mediated &lt;1%; skin test to confirm; 10√ó cross-reactivity with cephalosporins overstated (~2%)</li>
      <li>Venom allergy: systemic reaction to sting ‚Üí refer for venom immunotherapy (VIT); EpiPen prescribed</li>
    </ul>
  </div>

  <div class="progress-wrap">
    <div class="progress-label"><span>Study Progress</span><span id="progressText">0 / 12 opened</span></div>
    <div class="progress-bar"><div class="progress-fill" id="progressFill"></div></div>
  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION A: MECHANISMS & APPROACH -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section A ‚Äî Mechanisms of Allergic Disease</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="allergy mechanism IgE sensitization mast cell basophil histamine leukotrienes prostaglandins Th2 IL-4 IL-5 IL-13 atopy atopic march early late phase reaction allergen skin test RAST specific IgE">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 182</span>
        <span class="ch-title">Mechanisms of Allergic Disease</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Sensitization: first allergen exposure ‚Üí Th2 cytokines (IL-4, IL-13) ‚Üí B-cell class switch to <strong class="hl">IgE</strong> production ‚Üí IgE binds to high-affinity FcŒµRI receptors on <strong class="hl">mast cells and basophils</strong></li>
          <li class="imp">Re-exposure: allergen cross-links IgE on mast cells ‚Üí <strong class="hl">degranulation</strong> ‚Üí release of preformed mediators (histamine, tryptase, heparin) + newly synthesized mediators (prostaglandins, leukotrienes, PAF)</li>
          <li class="imp"><strong class="hl">Early phase</strong> (0‚Äì1h): mast cell degranulation ‚Üí histamine ‚Üí vasodilation, ‚Üëvascular permeability, smooth muscle contraction, mucus secretion; symptoms: itch, sneezing, wheezing, urticaria, angioedema</li>
          <li class="imp"><strong class="hl">Late phase</strong> (2‚Äì12h): eosinophil/neutrophil/T-cell recruitment ‚Üí IL-5, IL-13 ‚Üí sustained inflammation; chronic airway remodeling in asthma</li>
          <li class="imp">Key Th2 cytokines: <strong class="hl">IL-4</strong> (IgE class switching), <strong class="hl">IL-5</strong> (eosinophil development/survival), <strong class="hl">IL-13</strong> (mucus production, IgE class switching, airway hyperresponsiveness)</li>
          <li class="note">Atopic march: eczema (infancy) ‚Üí food allergy ‚Üí allergic rhinitis ‚Üí asthma; IgE-mediated sensitization precedes each step</li>
          <li class="note">Hygiene hypothesis: reduced childhood microbial exposures ‚Üí less Th1 stimulation ‚Üí excess Th2 ‚Üí ‚Üëatopy; explains ‚Üëallergy prevalence in developed countries</li>
          <li class="note">Diagnostic testing: <strong class="hl">skin prick test</strong> (most sensitive, immediate results); <strong class="hl">serum specific IgE (ImmunoCAP/RAST)</strong> ‚Äî useful when skin testing not possible; allergen provocation (oral food challenge) = gold standard for food allergy</li>
        </ul>
        <div class="mnemonic">Allergic reaction: "Sensitize ‚Üí IgE on Mast cells ‚Üí Re-expose ‚Üí Degranulate ‚Üí Histamine + Leukotrienes ‚Üí Symptoms"</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION B: ASTHMA             -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section B ‚Äî Asthma</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="asthma pathophysiology airway hyperresponsiveness inflammation remodeling reversible obstruction triggers viral rhinovirus allergen exercise cold air smoke FEV1 FVC spirometry peak flow methacholine bronchoprovocation">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 183</span>
        <span class="ch-title">Asthma: Pathophysiology &amp; Diagnosis</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Asthma: <strong class="hl">chronic inflammatory airway disease</strong> characterized by reversible airway obstruction, airway hyperresponsiveness (AHR), and airway inflammation; most common chronic disease of childhood</li>
          <li class="imp">Pathology: mucosal edema, smooth muscle hypertrophy, mucus hypersecretion, subepithelial fibrosis (remodeling), eosinophilic inflammation; goblet cell metaplasia</li>
          <li class="imp">Common triggers: <strong class="hl">viral URIs (rhinovirus #1)</strong>, allergens (dust mite, cockroach, mold, pet dander, pollen), exercise, cold air, cigarette smoke, pollutants, strong odors, GERD, aspirin/NSAIDs (in older children)</li>
          <li class="crit">Diagnosis: <strong class="hl">spirometry</strong> ‚Äî obstructive pattern: <strong class="hld">FEV‚ÇÅ/FVC &lt;0.8</strong> + <strong class="hld">‚â•12% improvement in FEV‚ÇÅ after bronchodilator</strong> (reversibility); peak flow monitoring</li>
          <li class="imp">If spirometry normal: <strong class="hl">methacholine bronchoprovocation challenge</strong> ‚Äî PC‚ÇÇ‚ÇÄ &lt;8 mg/mL confirms AHR; exercise challenge; FeNO (fractional exhaled NO) ‚Äî elevated in eosinophilic asthma</li>
          <li class="imp">Asthma phenotypes: <strong class="hl">allergic</strong> (most common, ‚ÜëIgE/eosinophils, Th2-driven), <strong class="hl">non-allergic</strong>, <strong class="hl">exercise-induced bronchoconstriction (EIB)</strong>, <strong class="hl">aspirin-exacerbated</strong> (Samter's triad: asthma + nasal polyps + aspirin sensitivity)</li>
          <li class="note">Early wheeze (virus-triggered, resolves by school age) vs persistent asthma (atopic, continues); API (Asthma Predictive Index) predicts persistence</li>
          <li class="note">Differential diagnosis: vocal cord dysfunction (inspiratory stridor, normal spirometry, responds to speech therapy), vascular ring, foreign body, tracheomalacia, CF, heart failure</li>
        </ul>
        <div class="mnemonic">Asthma spirometry: "FEV‚ÇÅ/FVC &lt;0.8 + &gt;12% bronchodilator response = confirmed reversible obstruction"</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="asthma management NAEPP GINA step therapy SABA albuterol ICS inhaled corticosteroid LABA salmeterol formoterol LTRA montelukast tiotropium biologics omalizumab dupilumab mepolizumab benralizumab tezepelumab oral corticosteroid controller reliever">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 184</span>
        <span class="ch-title">Asthma: Management &amp; Step Therapy</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">NAEPP classification: <strong class="hl">Intermittent</strong> (‚â§2 days/wk, ‚â§2 nights/mo, FEV‚ÇÅ ‚â•80%); <strong class="hl">Mild persistent</strong> (&gt;2 days/wk, 3‚Äì4 nights/mo); <strong class="hl">Moderate persistent</strong> (daily, &gt;1 night/wk, FEV‚ÇÅ 60‚Äì80%); <strong class="hl">Severe persistent</strong> (continuous, frequent nights, FEV‚ÇÅ &lt;60%)</li>
          <li class="crit">Step therapy (NAEPP 2020):</li>
          <li class="imp">Step 1 (Intermittent): <strong class="hl">SABA PRN</strong> (albuterol ‚Äî rescue only; short-acting Œ≤‚ÇÇ agonist)</li>
          <li class="imp">Step 2 (Mild persistent): <strong class="hl">low-dose ICS</strong> (inhaled corticosteroid ‚Äî most effective controller; e.g., fluticasone, budesonide) + SABA PRN; or LTRA (montelukast) if ICS not possible</li>
          <li class="imp">Step 3 (Moderate persistent): <strong class="hl">low-dose ICS + LABA</strong> (long-acting Œ≤‚ÇÇ agonist ‚Äî salmeterol/formoterol; never use LABA without ICS!) or medium-dose ICS</li>
          <li class="imp">Step 4: <strong class="hl">medium-dose ICS + LABA</strong></li>
          <li class="imp">Step 5: <strong class="hl">high-dose ICS + LABA</strong> ¬± biologics: <strong class="hl">omalizumab</strong> (anti-IgE, allergic asthma), <strong class="hl">mepolizumab/benralizumab</strong> (anti-IL-5/IL-5R, eosinophilic), <strong class="hl">dupilumab</strong> (anti-IL-4RŒ±, type 2), <strong class="hl">tezepelumab</strong> (anti-TSLP, severe uncontrolled)</li>
          <li class="imp">Step 6: Step 5 + oral corticosteroids (minimum dose, significant side effects)</li>
          <li class="crit"><strong class="hld">LABA black box warning</strong>: never use LABA as monotherapy (without ICS) ‚Äî ‚Üëasthma-related death; always combine with ICS</li>
          <li class="note">Inhaler technique: spacer/VHC essential for all children using MDI; DPI requires sufficient inspiratory flow (not recommended &lt;4‚Äì5 yrs); nebulizer for acute exacerbations</li>
          <li class="note">ICS side effects: oral candidiasis (rinse mouth after each use), dysphonia, minor growth suppression (dose-dependent, not clinically significant vs uncontrolled asthma)</li>
        </ul>
        <div class="mnemonic">Asthma steps: "SABA ‚Üí ICS ‚Üí ICS+LABA ‚Üí High-dose ICS+LABA ‚Üí Biologics ‚Üí Oral steroids" ‚Äî never LABA alone!</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="acute asthma exacerbation status asthmaticus emergency treatment albuterol ipratropium magnesium sulfate systemic steroids heliox NICU intubation PICU oxygen saturation pulsus paradoxus silent chest">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 185</span>
        <span class="ch-title">Acute Asthma Exacerbation &amp; Status Asthmaticus</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Severity assessment: mild (SABA responsive, SpO‚ÇÇ &gt;95%), moderate (partial response, SpO‚ÇÇ 90‚Äì95%, accessory muscle use), severe (minimal response, SpO‚ÇÇ &lt;90%, pulsus paradoxus &gt;12 mmHg)</li>
          <li class="crit"><strong class="hld">Silent chest</strong>: no wheezing in severe asthma = air movement too poor to generate wheeze = <strong class="hld">impending respiratory failure</strong> ‚Äî ominous sign!</li>
          <li class="crit">Emergency treatment ‚Äî all severe exacerbations:</li>
          <li class="imp">1. <strong class="hl">Supplemental O‚ÇÇ</strong> (target SpO‚ÇÇ ‚â•92‚Äì94%)</li>
          <li class="imp">2. <strong class="hl">Continuous nebulized albuterol</strong> (or frequent MDI with spacer) ¬± <strong class="hl">ipratropium bromide</strong> (anticholinergic ‚Äî additive bronchodilation, most benefit in first hour)</li>
          <li class="imp">3. <strong class="hl">Systemic corticosteroids</strong> (oral prednisolone or IV methylprednisolone) ‚Äî reduce inflammation, shorten hospitalization; onset 4‚Äì6h</li>
          <li class="crit">4. If severe/refractory: <strong class="hld">IV magnesium sulfate 25‚Äì75 mg/kg</strong> (smooth muscle relaxation, bronchodilation); <strong class="hl">heliox</strong> (helium-oxygen mixture ‚Äî ‚Üìairway resistance, buys time); IV terbutaline or aminophylline; consider NICU/intubation</li>
          <li class="imp">Status asthmaticus: severe asthma unresponsive to initial treatment; PICU admission; high-dose continuous bronchodilators, IV steroids, Mg, possible non-invasive ventilation</li>
          <li class="note">Pulsus paradoxus: ‚Üìsystolic BP &gt;10 mmHg with inspiration; reflects severe air trapping and ‚Üëintrathoracic pressure swings</li>
          <li class="note">Avoid sedation (‚Üìrespiratory drive), avoid antibiotics (viral trigger, not bacterial), avoid chest X-ray routinely (does not change management in typical exacerbation)</li>
        </ul>
        <div class="mnemonic">Acute asthma escalation: "O‚ÇÇ ‚Üí Albuterol + Ipratropium ‚Üí Steroids ‚Üí Magnesium ‚Üí Heliox ‚Üí ICU"</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="exercise induced bronchoconstriction EIB exercise induced asthma pre-treatment albuterol SABA warm up LABA montelukast post-exercise cough wheeze athletics sports">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 186</span>
        <span class="ch-title">Exercise-Induced Bronchoconstriction (EIB)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">EIB: transient airway narrowing triggered by vigorous exercise; affects 40‚Äì90% of children with asthma; can also occur without underlying asthma (EIB without asthma, especially in elite athletes)</li>
          <li class="imp">Mechanism: airway heat/water loss during exercise ‚Üí hyperventilation of cool dry air ‚Üí osmotic changes ‚Üí mast cell activation ‚Üí bronchoconstriction; peaks 5‚Äì15 min after exercise stops, resolves by 60 min</li>
          <li class="imp">Diagnosis: exercise challenge test ‚Äî ‚â•10% drop in FEV‚ÇÅ after standardized exercise protocol confirms EIB</li>
          <li class="imp">Treatment and prevention:</li>
          <li class="imp"><strong class="hl">SABA (albuterol) 15‚Äì30 min before exercise</strong> ‚Äî most effective pre-treatment; use as rescue if symptoms occur</li>
          <li class="note">Alternatives: LTRA (montelukast ‚Äî daily use), LABA (salmeterol) pre-exercise (not for daily use alone), inhaled sodium cromoglycate (mast cell stabilizer)</li>
          <li class="note">Non-pharmacologic: warm-up period, nose breathing (warms/humidifies air), scarf/balaclava in cold weather, avoid high-pollen days, prefer swimming (warm humid air)</li>
          <li class="note">If not responding to SABA: reconsider diagnosis ‚Äî vocal cord dysfunction (peaks during exercise, inspiratory stridor), cardiac causes, deconditioning, hyperventilation syndrome</li>
        </ul>
        <div class="mnemonic">EIB: "Wheeze peaks 5‚Äì15 min AFTER exercise stops ‚Üí SABA 15 min before exercise to prevent"</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION C: RHINITIS & SINUSITIS -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section C ‚Äî Allergic Rhinitis &amp; Rhinosinusitis</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="allergic rhinitis seasonal perennial dust mite pet dander pollen mold antihistamine intranasal corticosteroid INCS decongestant LTRA immunotherapy subcutaneous sublingual allergic shiners nasal crease turbinate">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 187</span>
        <span class="ch-title">Allergic Rhinitis</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Allergic rhinitis: most common chronic atopic disease; affects 10‚Äì30% of children; seasonal (trees spring, grass summer, weeds fall) or perennial (dust mite, cockroach, pet dander, mold)</li>
          <li class="imp">Symptoms: sneezing, rhinorrhea (clear), nasal congestion, pruritus (nose, eyes, palate), postnasal drip, anosmia</li>
          <li class="imp">Signs: <strong class="hl">allergic salute</strong> (upward rubbing of nose), <strong class="hl">nasal crease</strong> (horizontal line across nose), <strong class="hl">allergic shiners</strong> (infraorbital darkening ‚Äî venous congestion), <strong class="hl">cobblestoning</strong> (posterior pharynx), pale/bluish boggy turbinates, Dennie-Morgan lines (extra fold under eye)</li>
          <li class="crit">Treatment hierarchy: <strong class="hld">intranasal corticosteroids (INCS)</strong> ‚Äî most effective single agent (superior to antihistamines for nasal congestion); e.g., fluticasone, mometasone, budesonide; onset 1‚Äì2 weeks; minimal systemic absorption</li>
          <li class="imp">Antihistamines: <strong class="hl">second-generation</strong> (cetirizine, loratadine, fexofenadine) ‚Äî preferred (non-sedating, once daily); first-generation (diphenhydramine) ‚Äî sedating, impairs cognition/school performance, avoid</li>
          <li class="imp">Add-ons: <strong class="hl">LTRA (montelukast)</strong> ‚Äî useful if concurrent asthma; intranasal antihistamine (azelastine) ‚Äî rapid onset; decongestants (pseudoephedrine ‚Äî ‚â•12 yrs; avoid oxymetazoline &gt;3 days ‚Äî rebound rhinitis medicamentosa); intranasal cromoglycate (safe, less effective)</li>
          <li class="imp"><strong class="hl">Allergen Immunotherapy (AIT)</strong>: subcutaneous (SCIT) or sublingual (SLIT); disease-modifying ‚Äî induces tolerance; indicated for moderate-severe persistent allergic rhinitis not controlled by pharmacotherapy; 3‚Äì5 year course; only treatment that alters natural history</li>
          <li class="note">Nasal cytology: eosinophils on nasal smear ‚Üí allergic; neutrophils ‚Üí infectious; may help distinguish</li>
        </ul>
        <div class="mnemonic">Allergic rhinitis: "INCS beats antihistamines for congestion ‚Äî use second-gen antihistamines, NOT first-gen (sedating)"</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION D: ATOPIC DERMATITIS  -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section D ‚Äî Atopic Dermatitis</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="atopic dermatitis eczema filaggrin FLG skin barrier pruritus flexural distribution infantile childhood adult moisturizer emollient topical corticosteroid tacrolimus pimecrolimus dupilumab tralokinumab JAK inhibitor abrocitinib upadacitinib Staph aureus superinfection bleach bath">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 188</span>
        <span class="ch-title">Atopic Dermatitis (Eczema)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Atopic dermatitis (AD): most common inflammatory skin disease of children; affects 15‚Äì20% of children; strong association with asthma and allergic rhinitis (atopic march)</li>
          <li class="imp">Pathogenesis: <strong class="hl">filaggrin (FLG) gene mutations</strong> ‚Üí defective skin barrier ‚Üí trans-epidermal water loss ‚Üí allergen penetration ‚Üí Th2 inflammation (‚ÜëIL-4, IL-13, IL-31 ‚Äî pruritus); Th2 ‚Üí IgE sensitization ‚Üí ‚Üëatopy</li>
          <li class="imp">Distribution by age: <strong class="hl">infants</strong>: face, scalp, extensor surfaces; <strong class="hl">children</strong>: flexural creases (antecubital, popliteal fossa); <strong class="hl">adults</strong>: hands, eyelids, neck</li>
          <li class="imp">Diagnosis: clinical ‚Äî pruritus + chronic relapsing course + characteristic morphology/distribution + personal/family history of atopy (Hanifin-Rajka criteria)</li>
          <li class="crit">Treatment ladder:</li>
          <li class="imp">1. <strong class="hl">Moisturizers/emollients</strong>: cornerstone of management; apply liberally and frequently (especially immediately after bathing ‚Äî "soak and seal"); fragrance-free</li>
          <li class="imp">2. <strong class="hl">Topical corticosteroids (TCS)</strong>: first-line for flares; use lowest effective potency; avoid high-potency on face/folds/genitals; side effects: skin atrophy, striae, HPA suppression with prolonged use</li>
          <li class="imp">3. <strong class="hl">Topical calcineurin inhibitors (TCI)</strong>: tacrolimus, pimecrolimus ‚Äî steroid-sparing; safe for face/folds; no atrophy risk; FDA black box (theoretical lymphoma risk ‚Äî not clinically proven); use on sensitive areas or steroid-intolerant</li>
          <li class="crit">4. Moderate-severe AD: <strong class="hld">dupilumab (anti-IL-4RŒ±)</strong> ‚Äî FDA approved ‚â•6 months; blocks IL-4 and IL-13 signaling; most effective biologic; injected every 2‚Äì4 weeks; excellent safety profile</li>
          <li class="note">JAK inhibitors (abrocitinib, upadacitinib): oral; approved for moderate-severe AD ‚â•12 yrs; rapid onset; monitor for infections (herpes zoster), blood counts, lipids; black box: malignancy/thrombosis/CV risk</li>
          <li class="crit"><strong class="hl">Staphylococcus aureus superinfection</strong>: most common trigger of flares; colonizes &gt;90% of AD skin; treat flares with topical antibiotics (mupirocin), dilute bleach baths (‚Üìcolonization), systemic antibiotics if spreading cellulitis</li>
          <li class="note">Eczema herpeticum (Kaposi varicelliform eruption): HSV superinfection of eczematous skin ‚Üí punched-out erosions + fever; <strong class="hl">treat with systemic acyclovir</strong> ‚Äî potentially life-threatening</li>
        </ul>
        <div class="mnemonic">AD treatment: "Moisturize ‚Üí TCS flares ‚Üí TCI sensitive areas ‚Üí Dupilumab for moderate-severe" ‚Äî filaggrin defect = dry skin = moisturize!</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION E: FOOD ALLERGY       -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section E ‚Äî Food Allergy &amp; Gastrointestinal Allergic Disorders</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="food allergy IgE mediated non-IgE peanut milk egg tree nuts fish shellfish wheat soy sesame top 9 allergens FPIES FPIAP EoE eosinophilic esophagitis oral allergy syndrome OAS LEAP trial elimination diet oral food challenge OIT">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 189</span>
        <span class="ch-title">Food Allergy &amp; Gastrointestinal Allergic Disorders</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Food allergy: affects ~8% of children; <strong class="hl">Top 9 allergens</strong> (responsible for &gt;90% reactions): <strong class="hl">milk, egg, peanut, tree nuts, fish, shellfish, wheat, soy, sesame</strong> (added 2023); peanut most common trigger of fatal anaphylaxis</li>
          <li class="imp">IgE-mediated (immediate, within 2h): urticaria, angioedema, vomiting, anaphylaxis; skin prick test + specific IgE positive; management: strict avoidance + epinephrine auto-injector</li>
          <li class="imp">Natural history: milk/egg/wheat/soy often outgrown; peanut/tree nut/fish/shellfish usually lifelong; peanut tolerance outgrown in ~20%</li>
          <li class="imp"><strong class="hl">LEAP trial</strong>: early introduction of peanut-containing foods at 4‚Äì11 months in high-risk infants (severe eczema ¬± egg allergy) ‚Üí <strong class="hl">‚Üìpeanut allergy by 80%</strong>; current AAP recommendation: introduce peanut early for all infants; high-risk ‚Üí screen first with skin test or sIgE</li>
          <li class="crit"><strong class="hld">FPIES</strong> (Food Protein-Induced Enterocolitis Syndrome): non-IgE; profuse repetitive <strong class="hld">vomiting 1‚Äì4h</strong> after trigger (milk/soy most common; also solid foods ‚Äî rice, oats, meat); looks like sepsis; <strong class="hl">treat with ondansetron + IV NS</strong>; no skin test/sIgE (non-IgE); diagnosis by oral food challenge; most resolve by age 3‚Äì5</li>
          <li class="imp"><strong class="hl">FPIAP</strong> (Food Protein-Induced Allergic Proctocolitis): non-IgE; bloody mucoid stools in well-appearing breastfed infants; maternal milk protein elimination; resolves by 12 months</li>
          <li class="crit"><strong class="hld">Eosinophilic Esophagitis (EoE)</strong>: chronic immune-mediated esophageal inflammation driven by food antigens; ‚â•15 eosinophils/hpf on esophageal biopsy; symptoms: dysphagia, food impaction (older children), feeding difficulties/vomiting (infants); treat with <strong class="hl">PPI trial first</strong>, then topical swallowed steroids (fluticasone/budesonide slurry) or elimination diet (6-food or 2-food)</li>
          <li class="note"><strong class="hl">Oral Allergy Syndrome (OAS/pollen-food allergy)</strong>: IgE cross-reactivity between pollen and raw food proteins; itching/tingling of mouth/lips/throat immediately after eating raw fruits/vegetables; cooking destroys labile proteins ‚Äî cooked food tolerated; treat with antihistamines; not severe anaphylaxis risk typically</li>
          <li class="note"><strong class="hl">Oral Immunotherapy (OIT)</strong>: Palforzia (FDA-approved peanut OIT) ‚Äî desensitization by gradually increasing peanut protein dose; reduces severity of reactions if accidental exposure; does not cure; lifelong maintenance required</li>
        </ul>
        <div class="mnemonic">FPIES: "Profuse Vomiting 1‚Äì4h, Looks like Sepsis, non-IgE ‚Üí Ondansetron + IV fluids" ‚Äî no hives, no wheezing</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION F: ANAPHYLAXIS        -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section F ‚Äî Anaphylaxis</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="anaphylaxis epinephrine auto-injector EpiPen biphasic antihistamine corticosteroid allergen trigger food insect sting latex drug diagnosis criteria multisystem skin GI respiratory cardiovascular">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 190</span>
        <span class="ch-title">Anaphylaxis</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Anaphylaxis: severe, life-threatening systemic allergic reaction; requires ‚â•2 organ systems OR hypotension after known allergen exposure</li>
          <li class="imp">Diagnostic criteria (any ONE of three): 1) Acute onset with skin/mucosal + respiratory OR ‚ÜìBP; 2) ‚â•2 of: skin/mucosal, respiratory, ‚ÜìBP, GI symptoms after likely allergen exposure; 3) ‚ÜìBP after known allergen</li>
          <li class="crit"><strong class="hld">EPINEPHRINE IM (0.01 mg/kg, max 0.5 mg) anterolateral thigh = FIRST AND ONLY FIRST-LINE TREATMENT ‚Äî no delay, no exceptions</strong></li>
          <li class="crit">Antihistamines and corticosteroids are <strong class="hld">adjuncts only</strong> ‚Äî never substitute for epinephrine; they do NOT treat cardiovascular collapse or bronchospasm rapidly enough</li>
          <li class="imp">After epinephrine: position supine + legs elevated (unless vomiting/respiratory distress); IV fluid bolus (20 mL/kg) for hypotension; O‚ÇÇ; continuous monitoring; second epinephrine dose if needed (q5‚Äì15 min); albuterol for bronchospasm</li>
          <li class="crit"><strong class="hld">Biphasic anaphylaxis</strong>: recurrence of symptoms 4‚Äì12h (up to 72h) after apparent resolution; occurs in ~20%; observe ALL anaphylaxis patients ‚â•4‚Äì6h; some guidelines recommend 24h observation for severe reactions</li>
          <li class="imp">Triggers: food (peanut #1 in children), insect venom, medications (penicillin, NSAIDs, cephalosporins), latex, exercise (exercise-induced anaphylaxis ‚Äî often food + exercise cofactor), idiopathic</li>
          <li class="crit">Discharge: <strong class="hl">prescribe 2 epinephrine auto-injectors</strong> (EpiPen/Auvi-Q); educate on use; anaphylaxis action plan; allergen avoidance education; referral to allergist; medic-alert bracelet</li>
          <li class="note">Refractory anaphylaxis: glucagon (for patients on Œ≤-blockers ‚Äî bypasses Œ≤-receptor); vasopressors (norepinephrine); methylene blue; ECMO in extremis</li>
          <li class="note">Serum tryptase: peaks 60‚Äì90 min after anaphylaxis; helps confirm diagnosis retrospectively; mastocytosis if baseline ‚Üëtryptase + recurrent anaphylaxis</li>
        </ul>
        <div class="mnemonic">Anaphylaxis: "Epi FIRST, epi FAST, epi THIGH ‚Äî antihistamines and steroids are NEVER first-line!"</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION G: URTICARIA & ANGIOEDEMA -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section G ‚Äî Urticaria, Angioedema &amp; Other Allergic Conditions</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="urticaria hives angioedema acute chronic antihistamine IgE mast cell dermographism cold cholinergic pressure physical urticaria idiopathic H1 H2 blocker omalizumab dermatographism Quincke edema">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 191</span>
        <span class="ch-title">Urticaria &amp; Angioedema</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Urticaria (hives): transient, pruritic wheals (raised, erythematous, blanching); individual lesions last &lt;24h (if &gt;24h consider urticarial vasculitis); mast cell histamine release</li>
          <li class="imp"><strong class="hl">Acute urticaria (&lt;6 wks)</strong>: most common in children; usually IgE-mediated (food, drug, insect) or viral infection-triggered; often self-limited</li>
          <li class="imp"><strong class="hl">Chronic urticaria (‚â•6 wks)</strong>: <strong class="hl">idiopathic/spontaneous in 80‚Äì90%</strong> of cases; workup rarely reveals cause; autoimmune (anti-FcŒµRI IgG antibodies) in some</li>
          <li class="imp">Physical urticarias: <strong class="hl">dermatographism</strong> (skin writing ‚Äî most common physical urticaria; scratch produces wheals), cold (swimming risk ‚Äî anaphylaxis), cholinergic (small wheals with exercise/heat/stress), pressure, solar, aquagenic</li>
          <li class="crit">Treatment: <strong class="hl">second-generation H1 antihistamines</strong> (cetirizine, loratadine, fexofenadine) ‚Äî first-line, daily; can increase to 4√ó standard dose; add <strong class="hl">H2 blocker</strong> (ranitidine/famotidine) for refractory; <strong class="hl">omalizumab</strong> (anti-IgE) ‚Äî approved for chronic spontaneous urticaria ‚â•12 yrs refractory to antihistamines; rapid onset; very effective</li>
          <li class="imp">Angioedema: deeper dermal/submucosal swelling (lips, eyelids, tongue, GI tract, larynx); non-pitting, non-pruritic (vs urticaria which is pruritic); laryngeal angioedema = life-threatening ‚Üí epinephrine</li>
          <li class="crit">Angioedema WITHOUT urticaria: think <strong class="hld">hereditary angioedema (HAE)</strong> (C1-INH deficiency ‚Äî bradykinin-mediated, NOT histamine ‚Äî antihistamines ineffective!) or ACE inhibitor-induced (bradykinin ‚Äî stop ACE inhibitor immediately)</li>
          <li class="note">ACE inhibitor angioedema: bradykinin accumulation (ACE normally degrades bradykinin); more common in Black patients; treat with icatibant or fresh frozen plasma; switch to ARB (lower risk)</li>
        </ul>
        <div class="mnemonic">Angioedema without urticaria: "No Hives = No Histamine = Think Bradykinin = HAE or ACE inhibitor ‚Äî antihistamines won't work!"</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="insect sting allergy venom bee wasp yellow jacket hornet fire ant local reaction large local systemic anaphylaxis venom immunotherapy VIT EpiPen serum sickness">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 192</span>
        <span class="ch-title">Insect Sting Allergy &amp; Venom Immunotherapy</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Stinging insects: Hymenoptera order ‚Äî honeybee, bumble bee, yellow jacket (most common), wasp, hornets, fire ant (southeastern US)</li>
          <li class="imp">Reaction types: <strong class="hl">normal local</strong> (pain, swelling &lt;10 cm ‚Äî not allergic); <strong class="hl">large local</strong> (swelling &gt;10 cm, peaks 24‚Äì48h, lasts 3‚Äì10 days ‚Äî IgE mediated but not systemic); <strong class="hl">systemic/anaphylaxis</strong> (remote urticaria, angioedema, bronchospasm, shock ‚Äî true allergy)</li>
          <li class="crit">Systemic reaction management: epinephrine immediately; prescribe EpiPen √ó 2 at discharge; refer to allergist for venom testing and immunotherapy</li>
          <li class="crit"><strong class="hl">Venom Immunotherapy (VIT)</strong>: indicated for systemic reactions (not just large local); highly effective ‚Äî reduces risk of future anaphylaxis from ~60% to &lt;5%; 3‚Äì5 year course; children with cutaneous-only systemic reactions (urticaria only) have lower future risk and VIT may not be necessary</li>
          <li class="note">Honeybee: barbed stinger stays in skin ‚Üí remove immediately (scrape, don't squeeze); yellow jackets can sting multiple times</li>
          <li class="note">Fire ant: pustular papules characteristic (unique to fire ant ‚Äî not seen with other Hymenoptera); pseudopustules form 24h after sting; treat with topical steroids; anaphylaxis risk same</li>
          <li class="note">Mastocytosis: ‚Üëbaseline tryptase ‚Üí ‚Üëanaphylaxis risk with stings ‚Üí VIT strongly indicated; tryptase level should be checked in all systemic sting reactors</li>
        </ul>
        <div class="mnemonic">VIT indication: "Systemic reaction to sting ‚Üí VIT reduces future anaphylaxis risk from 60% to &lt;5%"</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="drug allergy penicillin cephalosporin cross-reactivity beta-lactam NSAID aspirin serum sickness Stevens-Johnson TEN drug rash eosinophilia DRESS sulfonamide anticonvulsant skin test drug challenge graded challenge desensitization">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 193</span>
        <span class="ch-title">Drug Allergy &amp; Adverse Drug Reactions</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Drug reactions: classified as predictable (dose-dependent ‚Äî most, e.g., side effects, toxicity) vs unpredictable (immunologic/idiosyncratic ‚Äî "drug allergy")</li>
          <li class="imp">Immunologic drug reactions: Type I (IgE ‚Äî anaphylaxis, urticaria), Type II (cytotoxic ‚Äî hemolytic anemia), Type III (serum sickness), Type IV (T-cell ‚Äî contact dermatitis, SJS/TEN, DRESS)</li>
          <li class="crit"><strong class="hld">Penicillin allergy</strong>: most commonly reported drug allergy (10% of patients); true IgE-mediated allergy in &lt;1%; ~80% lose allergy over 10 years; skin testing (major + minor determinants) most reliable; penicillin skin test negative ‚Üí can receive penicillin safely</li>
          <li class="imp">Penicillin-cephalosporin cross-reactivity: historically cited as ~10% ‚Äî now known to be <strong class="hl">~2%</strong> (shared R1 side chain, not Œ≤-lactam ring); patients with penicillin allergy can usually receive cephalosporins; higher risk with structurally similar R1 chains (amoxicillin-cefadroxil/cefprozil)</li>
          <li class="crit"><strong class="hld">DRESS</strong> (Drug Reaction with Eosinophilia and Systemic Symptoms): severe delayed reaction (2‚Äì8 wks after drug start); fever + widespread morbilliform rash + eosinophilia + lymphadenopathy + organ involvement (liver, kidney, heart, lung); drugs: aromatic anticonvulsants (phenytoin, carbamazepine, lamotrigine), allopurinol, sulfonamides, dapsone; treat: stop drug, systemic corticosteroids, IVIG; can be fatal</li>
          <li class="crit"><strong class="hld">SJS/TEN</strong>: see Part XII; mucous membrane involvement + epidermal detachment; stop culprit drug immediately; supportive care in burn unit; IVIG or cyclosporine for TEN</li>
          <li class="imp">Aspirin/NSAID reactions: Type A (pharmacologic ‚Äî GI irritation, renal effects), aspirin-exacerbated respiratory disease (AERD/Samter triad ‚Äî asthma + nasal polyps + aspirin sensitivity; leukotriene-mediated); true IgE-mediated NSAID allergy rare</li>
          <li class="note">Drug desensitization: gradual incremental dosing to induce temporary tolerance; useful when no alternative drug exists (e.g., penicillin for syphilis in pregnancy, carboplatin allergy); temporary ‚Äî must repeat if drug stopped</li>
          <li class="note">Graded challenge (test dose): for patients with low probability of true allergy; not for those with confirmed IgE-mediated reaction</li>
        </ul>
        <div class="mnemonic">DRESS: "2‚Äì8 weeks after drug + Rash + Eosinophilia + Organ damage = DRESS ‚Äî stop drug, give steroids"</div>
      </div>
    </div>

  </div>

  <div class="footer">
    <span>Nelson Textbook of Pediatrics ¬∑ 22nd Ed. ¬∑ 2024</span>
    <span>Part XIII: Chapters 182‚Äì193 ¬∑ Allergic Disorders</span>
  </div>

</div>

<script>
  let openedChapters = new Set();
  const TOTAL_CHAPTERS = 12;

  function toggleCard(header) {
    const card = header.parentElement;
    const wasOpen = card.classList.contains('open');
    card.classList.toggle('open');
    const chNum = card.querySelector('.ch-num').textContent;
    if (!wasOpen) openedChapters.add(chNum);
    updateProgress();
  }

  function updateProgress() {
    const opened = openedChapters.size;
    const pct = Math.min((opened / TOTAL_CHAPTERS) * 100, 100);
    document.getElementById('progressFill').style.width = pct + '%';
    document.getElementById('progressText').textContent = `${opened} / ${TOTAL_CHAPTERS} opened`;
  }

  function filterChapters() {
    const q = document.getElementById('searchInput').value.toLowerCase().trim();
    const cards = document.querySelectorAll('.chapter-card');
    let visible = 0;
    cards.forEach(card => {
      const title    = card.querySelector('.ch-title').textContent.toLowerCase();
      const body     = card.querySelector('.chapter-body') ? card.querySelector('.chapter-body').textContent.toLowerCase() : '';
      const keywords = (card.dataset.keywords || '').toLowerCase();
      if (!q || title.includes(q) || body.includes(q) || keywords.includes(q)) {
        card.classList.remove('hidden'); visible++;
      } else { card.classList.add('hidden'); }
    });
    document.getElementById('chapterCount').textContent = q
      ? `${visible} result${visible !== 1 ? 's' : ''}`
      : `${TOTAL_CHAPTERS} chapters`;
  }

  document.addEventListener('keydown', e => {
    if (e.ctrlKey && e.key === 'e') {
      e.preventDefault();
      document.querySelectorAll('.chapter-card:not(.open)').forEach(c => {
        c.classList.add('open');
        openedChapters.add(c.querySelector('.ch-num').textContent);
      });
      updateProgress();
    }
  });
</script>
</body>
</html>
